O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A(2022) Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study Gynecol Oncol(in press) DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709
Davidson B, Elstrand MB(2022) Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions Cytopathology(in press) DOI 10.1111/cyt.13126, PubMed 35398934
Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S(2022) Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification Gynecol Oncol, 165(2), 230-238 DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281
